Figure 5 | Blood Cancer Journal

Figure 5

From: Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model

Figure 5

Results of mouse experiments with L428-induced tumors. (a) Treatment schedule indicating intravenous (i.v.) injection of L428 cells, protein injection and days of measurement. (b) Relative tumor size after treatment with fusion proteins, as indicated. Tumor size was estimated by imaging with the Cri Maestro System. The mutant GbR201K-Ki4(scFv) caused a decelerated tumor growth as compared with the unspecific control GbR201-H22(scFv) (**) and to the wild-type Gb-Ki4(scFv) (*). The difference between Gb-Ki4(scFv) and GbR201K-H22(scFv) was not significant (ns). (c) Confocal microscopy of Ki4(scFv)-SNAP-BG-Vista-Green (i) stained tissue sections of control-treated L428 tumors, Kat2 signal from transfected cells is visible in red (ii) and the overlay of an enlarged image.

Back to article page